Abstract
Vindesine is a new, semisynthetic vinca alkaloid that has shown activity against nonsmall cell lung cancer in phase II trials conducted at several institutions. Regimens giving vindesine weekly at 3 mg/m2 i.v. x 5 weeks have been associated with the highest response rates. The vinca alkaloid can be administered in full doses when given with cisplatin, and a major response rate of 43% has been reported for the combination. The development of new drugs continues to be a major priority in the investigation and treatment of lung cancer.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 565-570 |
| Number of pages | 6 |
| Journal | Drugs under Experimental and Clinical Research |
| Volume | 8 |
| Issue number | 5 |
| State | Published - Jan 1 1982 |
ASJC Scopus subject areas
- Molecular Medicine
- Pharmacology
- Drug Discovery
- Pharmacology (medical)
